Healthcare

This bill requires physicians to be physically present in Texas during an in-person examination when providing abortion-inducing drugs to patients. It directly affects physicians who prescribe these drugs within Texas, prohibiting remote or telemedicine provision. The key mechanism mandates that a physician must be in the state and examine the patient at the time of drug administration, as specified in amended Health and Safety Code Section 171.063(b). Exceptions for out-of-state consultations (e.g., for non-abortion medical services) do not apply to abortion-inducing drugs, as clarified in amended Occupations Code Section 151.056(b-1).

HB 195 would add three substances - carisoprodol (a muscle relaxant), mifepristone (a medication used in medical abortions), and misoprostol (often used with mifepristone for abortions) - to Schedule IV of the Texas Controlled Substances Act. This change would regulate these substances under stricter state drug laws, affecting their legal possession, distribution, and use in Texas. The bill applies only to offenses committed on or after its effective date of January 1, 2026, with prior offenses governed by existing law. The policy change directly impacts healthcare providers, pharmacies, and individuals handling these specific medications within Texas.